ABSTRACT
OBJECTIVE@#To observe the clinical efficacy of " acupuncture" and oral estradiol and dydrogesterone tablets (femoston) on premature ovarian insufficiency of kidney deficiency.@*METHODS@#A total of 50 patients with premature ovarian insufficiency of kidney deficiency were randomized into an observation group and a control group, 25 cases in each one.In the observation group, " acupuncture" was applied at Baihui (GV 20), Zhongwan (CV 12), Guanyuan (CV 4), Qihai (CV 6), Zhongji (CV 3), Yaoyangguan (GV 3), Yaoshu (GV 2), Mingmen (GV 4), etc. once every 2 days, 1 month as a course. In the control group, femoston was prescribed for oral administration, one tablet per time, once a day, 1 month as a course. Both of the two groups were given consecutive treatment for 3 courses. Before and after treatment, the clinical symptoms, menstrual improvement as well as the changes of estradiol (E), luteotrophic hormone (LH) and follicle-stimulating hormone (FSH) in serum were observed in the two groups.@*RESULTS@#After treatment, the clinical symptoms and menstrual conditions were improved (<0.01), the levels of FSH and LH were significantly reduced (<0.01), and the levels of E were significantly increased in the two groups (<0.01). There were no significant difference in menstrual improvement rate and menstrual improvement time between the observation group and the control group (<0.05), the recurrence rate of menopause and clinical symptom score improvement in the observation group were superior to the control group (<0.05). In the observation group, the level of E in serum was lower and the levels of FSH and LH in serum were significantly lower than those in the control group (<0.05, <0.01). In the observation group, the rate of adverse reaction was 4.0% (1/25), which was lower than 36.0% (9/25) in the control group (<0.05).@*CONCLUSION@#" acupuncture" has better therapeutic effect for premature ovarian insufficiency of kidney deficiency. It is superior to femoston in improving clinical symptoms and recurrence rate of menopause as well as reducing the levels of FSH and LH.
Subject(s)
Female , Humans , Acupuncture Points , Acupuncture Therapy , Follicle Stimulating Hormone , Kidney Diseases , Therapeutics , Primary Ovarian Insufficiency , TherapeuticsABSTRACT
Objective To study and analyze the clinical efficacy of compound preparation Femoston for the treatment of perimenopausal syndrome in women. Methods 60 women with perimenopausal syndrome from April 2016 to July 2017 were selected and randomly divided into the control group and the experimental group, 30 cases for each group. The control group was given estradiol valerate tablets, and the experimental group was treated with compound preparation Femoston, one tablet a day. The treatment time of the two groups was 6 months, and the clinical efficacy of the experimental group and the control group were compared and analyzed. Results After the corresponding treatment, 4 patients were ineffective in the experimental group. In the control group, 7 patients were ineffective, 10 cases were effective, and 13 cases were good effective. The effective rate of the experimental group was 86.67%, which was significantly higher than that (76.67%) of the control group with statistical significance (P<0.05). The level of FSH in the experimental group was (24.10 ± 15.24) U/L, which was significantly better than that of the control group (42.72 ±15.56) U/L with statistical significance (P<0.05). There were no obvious adverse reactions in the two groups, and the rate of adverse reactions such as vomiting, abdominal pain and breast pain were 3.33% and 6.67%, respectively, and there was no statistical significance. Conclusion The clinical efficacy of compound preparation Femoston for treating perimenopausal syndrome is ideal. Femoston could significantly improve the hormone levels in patients with high safety.
ABSTRACT
Objective To study and analyze the clinical efficacy of compound preparation Femoston for the treatment of perimenopausal syndrome in women. Methods 60 women with perimenopausal syndrome from April 2016 to July 2017 were selected and randomly divided into the control group and the experimental group, 30 cases for each group. The control group was given estradiol valerate tablets, and the experimental group was treated with compound preparation Femoston, one tablet a day. The treatment time of the two groups was 6 months, and the clinical efficacy of the experimental group and the control group were compared and analyzed. Results After the corresponding treatment, 4 patients were ineffective in the experimental group. In the control group, 7 patients were ineffective, 10 cases were effective, and 13 cases were good effective. The effective rate of the experimental group was 86.67%, which was significantly higher than that (76.67%) of the control group with statistical significance (P<0.05). The level of FSH in the experimental group was (24.10 ± 15.24) U/L, which was significantly better than that of the control group (42.72 ±15.56) U/L with statistical significance (P<0.05). There were no obvious adverse reactions in the two groups, and the rate of adverse reactions such as vomiting, abdominal pain and breast pain were 3.33% and 6.67%, respectively, and there was no statistical significance. Conclusion The clinical efficacy of compound preparation Femoston for treating perimenopausal syndrome is ideal. Femoston could significantly improve the hormone levels in patients with high safety.
ABSTRACT
Objective To explore the clinical efficacy and safety of continuous sequential hormone replacement therapy of femoston for menopausal syndrome .Methods 121 cases of menopausal syndrome at expert outpatient service in our hospital from January 2014 to October 2015 received hormone replacement therapy of femoston for 24 weeks .Before and after treat-ment ,Kupperman score ,blood follicle stimulating hormone (FSH) ,estradiol (E2 ) ,luteinizing hormone (LH) and endometri-al thickness were determined .Results With the prolonging of treatment time ,patient's menopausal symptoms gradually re-lieved .Kupperman scores were declining .After 6 courses of treatment ,patient's menopausal symptoms completely eased . Kupperman scores decreased by 95 .0% (P<0 .01) ,serum FSH and LH decreased significantly (P<0.05 and P<0 .01) and serum E2 increased notably (P<0 .01) without endometrial thickness changes (P>0.05) .Conclusion Continuous sequential therapy of femoston can effectively relieve menopausal syndrome and control the menstrual cycle and the endocrine level without stimulating the endometrium excessively .
ABSTRACT
Objective To investigate application of femoston combined with Kuntai capsule in poor ovarian responders (PORs) receiving vitro fertilization. Methods 120 women with poor ovarian response after receiving IVF were s randomly elected. Pre-treatment with femoston plus Kuntai capsule was used for three menstrual cycles before the next cycle of assisted reproductive treatment. FSH, LH, E2, AMH, number of antral follicles, PSV, days of Gn, ampoules of Gn, cycle cancellation rate, E2 value of the day of HCG, follicle of less than 16mm, number of oocytes, fertilization rate, and number of good quality embryos were compared before and after treatment used. Results After pre-treatment, levels of FSH and LH were decreased, AMH, PSV were increased, E2 value of the day of HCG, number of antral follicles, follicle of less than 16 mm, oocytes, fertilization rate, and good quality embryos were increased; cycle cancellation rate was decreased, with significant differences (P< 0.05). Conclusions Femoston combined with kuntai capsule can effectively increase the functional reserve of the ovarian in poor ovarian responders, and can improve the outcome of IVF.